Icecure Medical Ltd ICCM

NAS: ICCM | ISIN: IL0011224156   8/07/2025
1,148 USD (+9,36%)
(+9,36%)   8/07/2025

6 mei 2025 · IceCure Receives High Level of Interest from Breast Surgeons at ASBrS 2025 Annual Meeting Following Recent Positive FDA Development on ProSense® Cryoablation · Persbericht

30 april 2025 · IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-Stage Breast Cancer · Persbericht

28 april 2025 · IceCure Exhibits ProSense® & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging Symposium · Persbericht

22 april 2025 · IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation · Persbericht

27 maart 2025 · IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America · Persbericht

24 maart 2025 · IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate · Persbericht

21 maart 2025 · IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025 · Persbericht

20 maart 2025 · IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense® Cryoablation in Early-Stage Breast Cancer · Persbericht

18 maart 2025 · IceCure's ProSense® Cryoablation Featured in Six Studies Presented at St. Gallen International Breast Cancer Conference · Persbericht

17 maart 2025 · IceCure Receives Notice of Allowance in China for Novel Cryogenic Pump for Next-Generation Cryoablation Technology · Persbericht

10 maart 2025 · Breast Cancer Patients who Underwent IceCure's ProSense® Cryoablation in Japan Reported Significantly Higher Satisfaction than Patients who Underwent Standard of Care Surgery · Persbericht

12 september 2024 · IceCure Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ProSense® in Early-Stage Low Risk Breast Cancer Scheduled for November 7, 2024 · Persbericht

4 september 2024 · IceCure to Meet Institutional Investors at the H.C. Wainwright and Lake Street Capital Markets Conferences · Persbericht

28 augustus 2024 · USPTO Grants Notice of Allowance for Additional Patent on IceCure's Novel Cryogenic Pump Technology: Reinforces IceCure's Global IP Leadership in Cryoablation Technologies · Persbericht

20 augustus 2024 · IceCure Medical Reports 20% Growth in ProSense® System and Probe Sales for the First Half of 2024; Reflects Continued Adoption in the U.S. and Other Global Markets · Persbericht

14 augustus 2024 · IceCure's ProSense® Destroyed 100% of Breast Cancer Tumors in Independent Study of Patients Who Chose Cryoablation Instead of Surgery · Persbericht

13 augustus 2024 · IceCure Medical to Report Second Quarter 2024 Financial & Operational Results on August 20, 2024 · Persbericht

7 augustus 2024 · IceCure Announces Positive Data from the Largest Multi-Institutional Study of its Kind: "Cryoablation of Primary Breast Cancer in Patients Ineligible for Clinical Trials" · Persbericht

22 juli 2024 · 99.74% Recurrence Free Rate for Women with Breast Cancer Treated with IceCure's ProSense® Cryoablation System: Key Findings Delivered at 32nd Annual Meeting of the Japanese Breast Cancer Society · Persbericht

19 juli 2024 · IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification · Persbericht

Mijn selecties